Janux Therapeutics, Inc.
JANX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for JANX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JANX
Janux Therapeutics, Inc. is a clinical-stage biotechnology company developing tumor-activated T cell engagers (TRACTr, TRACIr) and conditionally activated masked immunomodulators (ARM) for oncology and autoimmune diseases, with a focus on improving safety and efficacy over conventional T cell engagers.
Key risk: Capital depletion risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.10B
Cash Runway
—
Lead Asset
JANX007 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials for Janux Therapeutics, Inc..
Janux Therapeutics, Inc. is a clinical-stage biotechnology company developing tumor-activated T cell engagers (TRACTr, TRACIr) and conditionally activated masked immunomodulators (ARM) for oncology and autoimmune diseases, with a focus on improving safety and efficacy over conventional T cell engagers.
- Janux Therapeutics is developing a proprietary platform (TRACTr, TRACIr, ARM) designed to create conditionally activated T cell engagers with a large safety window and off-the-shelf format [sec_mda · as of 2025-11-06].
- The lead program, a CD19-ARM, has shown rapid, deep, and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset in non-human primates [sec_mda · as of 2025-11-06].
- As of June 30, 2026, the company reported cash and equivalents of $27.8M, total revenue of $10.3M, and a net loss of -$22.0M [sec].
- Key clinical programs include JANX007, JANX011, and JANX014, with future capital requirements dependent on trial progress and regulatory timelines [sec_mda · as of 2026-08-06].
- The company was incorporated in June 2017 and has devoted substantially all resources to organizing, staffing, and business development [sec_mda · as of 2025-11-06].
What works
- The TRACTr/TRACIr/ARM platform aims to overcome limitations of conventional T cell engagers by providing a large safety window and off-the-shelf format, potentially enabling higher dosing and improved performance [sec_mda · as of 2025-11-06].
- Preclinical data for the CD19-ARM program demonstrated rapid, deep, and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset, suggesting a differentiated profile [sec_mda · as of 2025-11-06].
- The company has multiple product candidates in development (JANX007, JANX011, JANX014), providing a pipeline that spans both oncology and autoimmune indications [sec_mda · as of 2026-08-06].
What to weigh
- The company has a history of net losses, reporting a net loss of -$22.0M for the six months ended June 30, 2026 [sec].
- Cash and equivalents of $27.8M as of June 30, 2026 may be insufficient to fund all planned clinical programs, and the company may need to raise additional capital [sec_mda · as of 2026-08-06].
- Clinical development is inherently uncertain, and the timing and costs of trials for JANX007, JANX011, and JANX014 could vary significantly, impacting capital requirements [sec_mda · as of 2026-08-06].
- The company has no approved products and relies entirely on the successful development and regulatory approval of its product candidates [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
The platform aims to create differentiated product candidates with a large safety window and off-the-shelf format.
“This platform aims to create differentiated product candidates that have a large safety window, off-the-shelf format positioning for higher dosing, rapid development and potential for improved performance.”
SEC MD&A · November 6, 2025
The lead CD19-ARM program showed rapid, deep, and durable B-cell depletion in non-human primates.
“The lead program, a CD19-ARM, has displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, supporting a potentially differentiated profile.”
SEC MD&A · November 6, 2025
Future capital requirements depend on clinical trial progress for JANX007, JANX011, and JANX014.
“Our future capital requirements will depend on many factors, including: • the initiation, trial design, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of our product candidates, and in particular the clinical trials for JANX007, JANX011 and JANX014;”
SEC MD&A · August 6, 2026
The company was incorporated in June 2017 and has focused on organizing and staffing.
“We were incorporated in June 2017. To date, we have devoted substantially all of our resources to organizing and staffing our company, busin”
SEC MD&A · November 6, 2025
Risks & what to watch (4)›
Key risks
- Capital depletion risk — Cash of $27.8M as of 2026-06-30 may not be sufficient to fund all planned clinical programs; additional financing may be needed [sec].
- Clinical trial uncertainty — Timing and costs of trials for JANX007, JANX011, and JANX014 are uncertain, which could affect capital requirements [sec_mda · as of 2026-08-06].
- No approved products — The company has no approved products and depends entirely on successful development and regulatory approval of its candidates [sec_mda · as of 2026-08-06].
- Platform validation risk — The TRACTr/TRACIr/ARM platform is still in clinical development; its ability to achieve a large safety window in humans is unproven [sec_mda · as of 2025-11-06].
What to watch
- Clinical data updates for JANX007, JANX011, and JANX014, as trial progress will impact capital needs and pipeline value [sec_mda · as of 2026-08-06].
- Cash runway and any future financing activities, given the $27.8M cash position as of 2026-06-30 [sec].
- Regulatory milestones, including FDA or other agency interactions for the lead programs [sec_mda · as of 2026-08-06].
- Preclinical and clinical validation of the CD19-ARM program's B-cell depletion profile in humans [sec_mda · as of 2025-11-06].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Janux Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Janux Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.09 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
190
Total value held
$895.6M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 11,189,693 | $155.5M |
| janus henderson group plc | 8,392,818 | $116.6M |
| blackrock, inc. | 5,433,233 | $75.5M |
| vanguard capital management llc | 3,622,730 | $50.4M |
| prosight management, lp | 3,550,000 | $49.3M |
| fmr llc | 2,535,724 | $35.2M |
| state street corp | 2,464,017 | $34.2M |
| alyeska investment group, l.p. | 1,601,089 | $22.3M |
| wellington management group llp | 1,597,650 | $22.2M |
| woodline partners lp | 1,476,064 | $20.5M |
Showing top 10 of 190 institutional holders of Janux Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 17.5%
- Days to cover
- 6.3
- Shares short
- 7,440,069
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JANX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Janux Therapeutics, Inc.?
Janux Therapeutics, Inc. is a clinical-stage biotechnology company developing tumor-activated T cell engagers (TRACTr, TRACIr) and conditionally activated masked immunomodulators (ARM) for oncology and autoimmune diseases, with a focus on improving safety and efficacy over conventional T cell engagers.
What is Janux Therapeutics, Inc.'s lead drug candidate?
Janux Therapeutics, Inc.'s most advanced tracked candidate is JANX007 (Phase 1) for Prostate Cancer.
Who is the CEO of Janux Therapeutics, Inc.?
Dr. David Alan Campbell Ph.D. is the chief executive officer of Janux Therapeutics, Inc. (JANX).
Where is Janux Therapeutics, Inc. headquartered?
Janux Therapeutics, Inc. (JANX) is headquartered in San Diego, CA, United States.
What therapeutic areas does Janux Therapeutics, Inc. focus on?
Janux Therapeutics, Inc. develops therapies across Oncology, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.